Since efgartigimod treatment efficiently rescues the loss of keratinocyte adhesion upon anti-Dsg3 antibody and PV IgG treatment, our data strongly support the use of efgartigimod in the treatment of PV and suggest that stabilization of keratinocyte adhesion may present a novel treatment paradigm for pemphigus. The gene discussed is DSG3; the disease is acquired polycythemia vera.